Therapy of Graves’ disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism

1991 ◽  
Vol 14 (10) ◽  
pp. 847-851 ◽  
Author(s):  
Enio Martino ◽  
S. Balzano ◽  
L. Bartalena ◽  
A. Loviselli ◽  
V. Sica ◽  
...  
Keyword(s):  
Recurrence Rate ◽  
High Recurrence Rate ◽  
Graves Disease ◽  
Sodium Ipodate

scholarly journals Prediction of Relapse After Antithyroid Drugs Withdrawal: A Narrative Review

2020 ◽  
Vol 18 (Suppl) ◽  
Author(s):  
Pei-Wen Wang
Keyword(s):  
Risk Factors ◽  
Recurrence Rate ◽  
Prediction Models ◽  
Clinical Signs ◽  
Human Leukocyte ◽  
Baseline Risk ◽  
Antithyroid Drugs ◽  
Prior History ◽  
High Recurrence Rate ◽  
Graves Disease

Context: Antithyroid drugs (ATD) are the first-line treatment for Graves’ disease (GD); however, relapse following treatment is approximately 30% - 40% in the first year, and 50% - 60% in the long term. Identification of risk factors that predict relapse, after discontinuing ATD, plays an important role in guiding therapeutic options. Evidence Acquisition: PubMed was used to search for studies published in English between 1995 and 2019. The following search terms were used: Graves’ disease, antithyroid drugs, relapse, recurrence, and outcome. The reference lists from review articles were also included in the search in order to find older journals. Results: Factors associated with a high recurrence rate, as reported in most studies, were divided into phenotype and genotype predictors. Phenotype factors included large goiter size, persistence of high TSH receptor antibody (TRAb), severe hyperthyroidism, smoking, younger age, male sex, and prior history of recurrence. Genotype factors included human leukocyte antigen (HLA), CD40, CTLA-4, PTPN22, Tg, and TSHR genes. In a subgroup analysis by age, genetic factors were better predictors in the younger group, while clinical signs were more useful in the older group. The reliability of using individual baseline risk factors to predict subsequent relapse is poor; however, predictive scores calculated by grouping single risk factors might help to predict future outcomes. Conclusions: Longer normalization time of TRAb, the persistence of a palpable goiter, and harboring genetic risk factors in younger patients are associated with high recurrence rate of GD. Multi-marker prediction models have been proposed and validated to improve the predictive value of relapse after ATD withdrawal.

scholarly journals Antithyroid Drug Therapy for Graves’ Disease and Implications for Recurrence

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Jia Liu ◽  
Jing Fu ◽  
Yuan Xu ◽  
Guang Wang
Keyword(s):  
Recurrence Rate ◽  
Influencing Factors ◽  
Current Knowledge ◽  
Antithyroid Drug ◽  
Immunosuppressive Drugs ◽  
Antithyroid Drugs ◽  
High Recurrence Rate ◽  
Graves Disease ◽  
Immune Disorder ◽  
Modifiable Factors

Graves’ disease (GD) is the most common cause of hyperthyroidism worldwide. Current therapeutic options for GD include antithyroid drugs (ATD), radioactive iodine, and thyroidectomy. ATD treatment is generally well accepted by patients and clinicians due to some advantages including normalizing thyroid function in a short time, hardly causing hypothyroidism, and ameliorating immune disorder while avoiding radiation exposure and invasive procedures. However, the relatively high recurrence rate is a major concern for ATD treatment, which is associated with multiple influencing factors like clinical characteristics, treatment strategies, and genetic and environmental factors. Of these influencing factors, some are modifiable but some are nonmodifiable. The recurrence risk can be reduced by adjusting the modifiable factors as much as possible. The titration regimen for 12–18 months is the optimal strategy of ATD. Levothyroxine administration after successful ATD treatment was not recommended. The addition of immunosuppressive drugs might be helpful to decrease the recurrence rate of GD patients after ATD withdrawal, whereas further studies are needed to address the safety and efficacy. This paper reviewed the current knowledge of ATD treatment and mainly focused on influencing factors for recurrence in GD patients with ATD treatment.

scholarly journals Serum TSH level as predictor of Graves’ disease recurrence following antithyroid drug withdrawal: A systematic review

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0245978
Author(s):  
Imam Subekti ◽  
Gracia Jovita Kartiko ◽  
Zahra Farhanni Suhardi ◽  
Muhadi ◽  
Wismandari Wisnu
Keyword(s):  
Recurrence Rate ◽  
Antithyroid Drug ◽  
Disease Recurrence ◽  
Thyroid Stimulating Hormone ◽  
Treatment Withdrawal ◽  
High Recurrence Rate ◽  
Graves Disease ◽  
Adequate Treatment ◽  
Risk Of Disease

Graves’ disease (GD) has a high recurrence rate despite various and adequate treatment. Numerous studies have been performed to identify the predictor of disease recurrence. This report aims to investigate the role of thyroid stimulating hormone (TSH) level as a thyrotropin in predicting the recurrence of Graves’ disease within 1 to 2 years following antithyroid drug (ATD) withdrawal. Literature searching was conducted on PubMed, Scopus, Cochrane, Proquest, EBSCO in August 2019 and Google Scholar in October 2020. The study criteria include the study that evaluates TSH level 4 weeks following ATD withdrawal, with subjects ≥18 years old who are retrospectively or prospectively followed up after 1 to 2 years following ATD withdrawal. Four eligible studies were selected based on inclusion/exclusion criteria, all of which measured TSH level at 4 weeks following ATD withdrawal. All studies had 1 to 2 years follow up. One study was an RCT, two studies were done in prospective cohort and another in retrospective cohort. All studies had comparable validity and applicability. Three out of four studies suggested that low TSH level measured 4 weeks following treatment withdrawal was associated with higher risk of disease recurrence. In conclusion, low TSH level obtained 4 weeks after ATD withdrawal was associated with higher rate of recurrence rate in GD.

scholarly journals Immunoglobulin-E and Thyroid-Stimulating Hormone Receptor Antibody in Graves’ disease with Atopy

2021 ◽  
Vol 129 (s2) ◽  
Author(s):  
Rio Wironegoro ◽  
Ari Baskoro ◽  
Chairul Effendi ◽  
Agung Pranoto
Keyword(s):  
Recurrence Rate ◽  
Hormone Receptor ◽  
Immunoglobulin E ◽  
Pollen Allergy ◽  
Thyroid Stimulating Hormone ◽  
High Recurrence Rate ◽  
Graves Disease ◽  
Receptor Antibody ◽  
History Of ◽  
Stimulating Hormone

Background: Graves’ disease is known to have a high recurrence rate with recent evidence linked pollen allergy as one of the factors that might induce relapse in Graves’ disease. Therefore, it was argued that IgE might play a role in inducing relapse of Graves’ Disease. This study aims to investigate the correlation between IgE and Thyroid-Stimulating Hormone ReceptorAntibody (TRAb) in Graves’ disease respondents with a history of atopy.

Modern molecular and biological aspects of endometriosis-associated infertility

GYNECOLOGY ◽  
2019 ◽  
Vol 21 (5) ◽  
pp. 12-15
Author(s):  
Anastasiia S Safronova ◽  
Mikhail Yu Vysokikh ◽  
Vladimir D Chuprynin ◽  
Natalia A Buralkina
Keyword(s):  
Signaling Pathways ◽  
Recurrence Rate ◽  
High Recurrence Rate ◽  
Modern Drug ◽  
Surgical Methods ◽  
Prevention And Treatment ◽  
Biological Aspects ◽  
Methods Of Treatment ◽  
New Strategies

There is currently no consensus on the etiopathogenetic nature of endometriosis. The causes of aggressive, progressive, infiltrative growth of endometrioid tissue also remain unclear. An important problem remains the high recurrence rate of endometriosis, despite the availability of modern drug and surgical methods of treatment. The study of the central signaling pathways and the search for new key molecules is of paramount importance for a better understanding of the pathogenesis of the disease, and is also an important step in the development of new strategies for the diagnosis, prevention and treatment of endometriosis.

scholarly journals Retrospective Evaluation of Claw Lesions, Inflammatory Markers, and Outcome After Abomasal Rolling in Cattle with Left Displacement of the Abomasum

Animals ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1648
Author(s):  
Theresa Tschoner ◽  
Yury Zablotski ◽  
Melanie Feist
Keyword(s):  
Recurrence Rate ◽  
Surgical Procedures ◽  
Medical Records ◽  
Inflammatory Markers ◽  
Post Partum ◽  
High Recurrence Rate ◽  
Retrospective Evaluation ◽  
Analgesic Treatment ◽  
Temporary Relief ◽  
Claw Lesions

Lameness is often diagnosed in cattle with left displacement of the abomasum (LDA). Laterality of lying has an effect on the etiology of LDA, and lame cows prefer to lie on the affected limb. The objective of this study was to investigate the possible association between laterality of claw lesion and presence of LDA. The medical records of 252 cattle presented with a diagnosis of LDA and subjected to a diagnostic examination of claw lesions over a period of 11 years (2009–2019), were analyzed retrospectively. Data were evaluated for presence and localization of claw lesion, concentrations of inflammatory markers, and abomasal rolling as therapy. At least one claw lesion was diagnosed in 46.4% of cattle. There was no association between laterality of claw lesion and LDA. Presence of claw lesion or oral drench and/or analgesic treatment did not have an effect on occurrence of relapse. A high number of cattle was diagnosed with both LDA and claw lesions. Focus should lie on preventing painful claw lesions in the dry and the early post-partum period. The high recurrence rate after abomasal rolling suggests that abomasal rolling should only be considered as a therapy for temporary relief, and surgical procedures should be discussed with farmers.

High recurrence rate after posterior component separation and keyhole mesh reconstruction for complex parastomal hernia: a case series study.

2021 ◽  
Author(s):  
Alvaro Robin Valle de Lersundi ◽  
Niccolo Ruppealta ◽  
Carlos San Miguel Mendez ◽  
Joaquin Muñoz Rodriguez ◽  
Marina Pérez Flecha ◽  
...  
Keyword(s):  
Recurrence Rate ◽  
Parastomal Hernia ◽  
Case Series ◽  
Component Separation ◽  
High Recurrence Rate ◽  
Posterior Component Separation ◽  
Case Series Study ◽  
Mesh Reconstruction ◽  
Series Study

Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease

Metabolism ◽  
1993 ◽  
Vol 42 (4) ◽  
pp. 403-408 ◽  
Author(s):  
Elio Roti ◽  
Eliana Gardini ◽  
Roberta Minelli ◽  
Lina Bianconi ◽  
Lewis E. Braverman
Keyword(s):  
Term Treatment ◽  
Graves Disease ◽  
Long Term Treatment ◽  
Sodium Ipodate

EFFECT OF THE COMBINATION OF DEXAMETHASONE AND SODIUM IPODATE ON SERUM THYROID HORMONES IN GRAVES' DISEASE

1983 ◽  
Vol 19 (5) ◽  
pp. 619-627 ◽  
Author(s):  
E. ARTEAGA ◽  
J. M. LÓPEZ ◽  
J. A. RODRÍGUEZ ◽  
P. MICHAUD ◽  
G. LÓPEZ
Keyword(s):  
Thyroid Hormones ◽  
Graves Disease ◽  
Sodium Ipodate ◽  
Serum Thyroid Hormones
Sign in / Sign up

Export Citation Format

Share Document